Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. enVVeno Medical's Total Liabilities for the quarter that ended in Jun. 2026 was $1.99 Mil. enVVeno Medical's Total Assets for the quarter that ended in Jun. 2026 was $22.66 Mil.
Therefore, enVVeno Medical's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.09.
enVVeno Medical (NAS:NVNOW) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
enVVeno Medical Liabilities-to-Assets Related Terms
enVVeno Medical Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for enVVeno Medical's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVNOW vs ICCM, TRIB, AIDX: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, enVVeno Medical's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
enVVeno Medical's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical (NVNOW) has a Liabilities-to-Assets of 0.09 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on enVVeno Medical and its competitors.
Is enVVeno Medical's Liabilities-to-Assets too high?
enVVeno Medical's current Liabilities-to-Assets is 0.09. Overall, enVVeno Medical has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's Liabilities-to-Assets compare to ICCM and TRIB?
enVVeno Medical's Liabilities-to-Assets of 0.09 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on enVVeno Medical and its competitors. enVVeno Medical's current Liabilities-to-Assets is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNOW) has a current Liabilities-to-Assets of 0.09. The current Liabilities-to-Assets is 0.09. enVVeno Medical's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For enVVeno Medical (NVNOW), the current Liabilities-to-Assets is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
30GF Score
Get the complete analysis for NVNOW
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNOW has been successfully added to your 
